

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on 3-1-07

PATENT
Attorney Docket No.: 020681-000410US

TOWNSEND and TOWNSEND and CREW LLP

By: Fruida Sheffer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hans Hofland *et al.*

Application No.: 10/713,787

Filed: November 13, 2003

For: OPHTHALMIC LIPOSOME
COMPOSITIONS AND USES
THEREOF

Customer No.: 20350

Confirmation No. 8755

Examiner: Gollamudi S. Kishore

Technology Center/Art Unit: 1615

**RESPONSE TO RESTRICTION
REQUIREMENT AND PRELIMINARY
AMENDMENT**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement mailed February 1, 2007, Applicants elect, with traverse, to prosecute the claims of Group II, , claims 31-50, drawn to methods for treating or preventing ophthalmic disorders and to methods for treating or preventing ocular inflammation. Further, in response to the Examiner's request for a Species Elections, Applicants elect for purposes of examination only, the following species: the method of treating an ophthalmic disorder, wherein the ophthalmic disorder is ocular inflammation (*see*, claims 1, 33, 34, 35, 36 and 43-50), and the therapeutic agent is diclofenac (*see*, claims 41, 42, 46 and 48).

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 9 of this paper.